LMK-235

LMK-235 is a potent and selective HDAC4/5 inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC50s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.

Product Specifications

CAS Number

[1418033-25-6]

UNSPSC

12352005

Hazard Statement

H302

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LMK-235.html

Purity

99.61

Solubility

DMSO : 175 mg/mL (ultrasonic)

Smiles

O=C(NOCCCCCC(NO)=O)C1=CC(C)=CC(C)=C1

Molecular Formula

C15H22N2O4

Molecular Weight

294.35

Precautions

H302

References & Citations

[1]Marek L, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56 (2) :427-36.|[2]Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2016 Jun 21;7 (25) :37966-37978.|[3]Trazzi S, et al. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Hum Mol Genet. 2016 Sep 15;25 (18) :3887-3907.